Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Clinical Oncology

• Publication date

  2004-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2004.11.037PMID 15051767
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

  2004cited by this paper
• A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

  2004cited by this paper
• Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group.

  2004cited by this paper
• 1088 Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI group study 40986

  2003cited by this paper
• Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.

  2003cited by this paper
• Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial.

  2003cited by this paper
• Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.

  2002cited by this paper
• Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.

  2002cited by this paper
• Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.

  2002cited by this paper
• Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.

  2002cited by this paper
• Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC)

  2002cited by this paper
• Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

  2001cited by this paper
• Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.

  2001cited by this paper
• New chemotherapy approaches in colorectal cancer

  2001cited by this paper
• Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

  2000cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper
• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

  2000cited by this paper
• Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.

  1998cited by this paper
• Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.

  1998cited by this paper
• Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

  1998cited by this paper

• Photodynamic Therapy for Colorectal Cancer: A Bibliometric and Visualization Analysis (1986-2025).

  2026cites this paper
• Nutritional Supplement Ocoxin® Combined with Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer

  2025cites this paper
• Integrative Naturopathic Treatment Model for Colorectal Cancer: A Retrospective Study

  2025cites this paper
• Observational study on the efficacy and safety of FOLFOXIRI therapy for locally advanced rectal cancer: The Kanagawa Yokohama Colorectal Cancer Study Group (KYCC)1802

  2025cites this paper
• Evodiamine Enhances Chemosensitivity in Colorectal Cancer by Targeting Ribonucleotide Reductase M2

  2025cites this paper
• Patient and Clinician Views on Risk Prediction for Chemotherapy-Induced Peripheral Neuropathy.

  2025cites this paper
• Case Report: Coronary vasospasm precipitating STEMI and polymorphic ventricular tachycardia—a case of cardiotoxicity from 5-FU based chemotherapy in a 41-year-old woman

  2025cites this paper
• Personalizing colorectal Cancer treatment: Chemotherapy drug testing with patient-derived tumor cell clusters

  2025cites this paper
• Production of novel theranostic nano-vector based on superparamagnetic iron oxide nanoparticles/miR-497 targeting colorectal cancer

  2025cites this paper
• Effect of pretreatment vascular endothelial growth factor inhibitor use on the safety and efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer

  2025cites this paper
• The adverse reactions of bevacizumab in combination with the FOLFOX chemotherapy regimen in metastatic colorectal cancer.

  2025cites this paper
• Advances in pharmacotherapy for the treatment of peritoneal metastases from colorectal cancer

  2024cites this paper
• Long-Term Outcome After Resection of Hepatic and Pulmonary Metastases in Multivisceral Colorectal Cancer

  2024cites this paper
• Recent advancements in Nanotechnology-Mediated Platinum-Based cancer therapy

  2024cites this paper
• Causes of death in patients operated for colorectal cancer.

  2024cites this paper
• Unveiling the Intermolecular Interactions between Drug 5-Fluorouracil and Watson–Crick/Hoogsteen Base Pairs: A Computational Analysis

  2024cites this paper
• Management of Metastatic Colorectal Cancer (mCRC): Real-World Recommendations

  2024cites this paper
• Orosomucoid 2 upregulation mediates liver injury‐induced colorectal cancer liver metastasis by promoting EMT and cell migration

  2024cites this paper
• Raltitrexed Chemotherapy Regimen Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer: A Prospective Multicenter Phase II Trial

  2024cites this paper
• Consensus Statements for Clinical Practice in Advanced/Metastatic Colorectal Cancers in India Using a Modified Delphi Method

  2024cites this paper
• Sweeten the pill: Multi-faceted polysaccharide-based carriers for colorectal cancer treatment.

  2024cites this paper
• Long-Term Follow-up Data of a Multi-Institutional Phase-2 Study of S-1/oxaliplatin and Bevacizumab Therapy in Patients with Advanced Colorectal Cancer: The HiSCO-02 Study.

  2024cites this paper
• Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review

  2024cites this paper
• Isthmin-1 promotes growth and progression of colorectal cancer through the interaction with EGFR and YBX-1.

  2024cites this paper
• Organoid models of breast cancer in precision medicine and translational research

  2024cites this paper
• Veliparib (ABT-888), a PARP inhibitor potentiates the cytotoxic activity of 5-fluorouracil by inhibiting MMR pathway through deregulation of MSH6 in colorectal cancer stem cells

  2023cites this paper
• Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal Cancer

  2023cites this paper
• Role of cGAS-STING in colorectal cancer: A new window for treatment strategies.

  2023cites this paper
• The Five-year KRAS, NRAS and BRAF Analysis Results and Treatment Patterns in Daily Clinical Practice in Slovenia in 1st Line Treatment of Metastatic Colorectal (mCRC) Patients with RAS Wild-type Tumour (wtRAS) – A Real- Life Data Report 2013–2018

  2023cites this paper
• Clusterin Expression in Colorectal Carcinomas

  2023cites this paper
• Comparative Analysis of First-Line FOLFOX Treatment With and Without Anti-VEGF Therapy in Metastatic Colorectal Carcinoma: A Real-World Data Study

  2023cites this paper
• Effectiveness of Biologic Agents Among Hispanic Patients With Metastatic Colorectal Cancer.

  2023cites this paper
• Integrative analysis revealed that distinct cuprotosis patterns reshaped tumor microenvironment and responses to immunotherapy of colorectal cancer

  2023cites this paper
• Outcomes Following Treatment with FOLFOX for Patients with Resectable or Potentially Resectable Metastatic Colorectal Cancer: A Population-based Cohort Study.

  2023cites this paper
• Advances in systemic chemotherapy and immunotherapy for metastatic colorectal cancer

  2023cites this paper
• CT-based Radiomics for the Identification of Colorectal Cancer Liver Metastases Sensitive to First-Line Irinotecan-Based Chemotherapy.

  2023cites this paper
• Presentation of Colorectal Carcinoma as Abdominal Wall Phlegmon

  2023cites this paper
• Abdominal Aortic Aneurysm Repair in Patients with Concomitant Cancer: A Literature Review

  2023cites this paper
• Prediction of Clinical Precision Chemotherapy by Patient‐Derived 3D Bioprinting Models of Colorectal Cancer and Its Liver Metastases

  2023cites this paper
• Delayed Versus Immediate Start of Chemotherapy in Asymptomatic Patients With Advanced Cancer: A Meta-Analysis

  2023cites this paper
• Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer

  2023cites this paper
• The Orexin receptors: Structural and anti-tumoral properties

  2022cites this paper
• Zebrafish Patient-Derived Xenograft Model to Predict Treatment Outcomes of Colorectal Cancer Patients

  2022cites this paper
• Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in colorectal carcinoma at high risk of peritoneal carcinomatosis: short-term and long-term outcomes from the CHECK study – protocol for a randomised, multicentre, phase 3 trial

  2022cites this paper
• Resource Oriented Decision Making for Treatment of Metastatic Colorectal Cancer (mCRC) in a Lower-Middle Income Country: Egyptian Foundation of Medical Sciences (EFMS) Consensus Recommendations 2020

  2022cites this paper
• Prognostic Factors of Bone Metastases From Colorectal Cancer in the Era of Targeted Therapy

  2022cites this paper
• Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years.

  2022cites this paper
• LINC00022 acts as an oncogene in colorectal cancer progression via sponging miR-375-3p to regulate FOXF1 expression

  2022cites this paper
• FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial

  2022cites this paper
• Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement

  2022cites this paper
• A roadmap for medical treatment of metastatic CRC

  2022cites this paper
• Aldehyde Dehydrogenase 2 Family Member (ALDH2) Is a Therapeutic Index for Oxaliplatin Response on Colorectal Cancer Therapy with Dysfunction p53

  2022cites this paper
• LINC00022 acts as an oncogene in colorectal cancer progression via sponging miR-375-3p to regulate FOXF1 expression

  2022cites this paper
• Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis

  2022cites this paper
• Patient‐Derived Organoids from Colorectal Cancer with Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy

  2022cites this paper
• Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†.

  2022cites this paper
• Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)

  2021cites this paper
• Accuracy of Using a Patient-Derived Tumor Organoid Culture Model to Predict the Response to Chemotherapy Regimens In Stage IV Colorectal Cancer

  2021cites this paper
• A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study

  2021cites this paper
• Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

  2021cites this paper
• GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer

  2021cites this paper
• Significance of Radiofrequency Ablation for Unresectable Colorectal Cancer With Liver Metastases

  2021cites this paper
• Clinical Progress in Inoperable or Recurrent Advanced Gastric Cancer Treatment from 1004 Single Institute Experiences Between 2007 and 2018

  2021cites this paper
• Prognostic Prediction Models for Liver Metastasis and Overall Survival in Colorectal Cancer Patients

  2021cites this paper
• Tumor cell apoptosis mediated by the orexins

  2021cites this paper
• The price of curing cancer

  2021cites this paper
• Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer

  2021cites this paper
• Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target

  2021cites this paper
• Optimal solutions in the third line therapy for refractory metastatic colorectal cancer. CORRECTness and CONCURency

  2021cites this paper
• Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer.

  2021cites this paper
• Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era

  2021cites this paper
• Long Term Real-World Outcomes of Trifluridine/Tipiracil in Metastatic Colorectal Cancer—A Single UK Centre Experience

  2021cites this paper
• Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread

  2021cites this paper
• Risk–benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer

  2021cites this paper
• Prognostic value of regional lymph node involvement in patients with metastatic colorectal cancer: palliative versus curative resection

  2021cites this paper
• Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II).

  2021cites this paper
• Survival Advantage of Yttrium-90 Radioembolization to Systemic Therapy in Patients with Hepatic Metastases from Colorectal Cancer in the Salvage Setting: Results of a Matched Pair Study.

  2021cites this paper
• Rigosertib elicits potent anti-tumor responses in colorectal cancer by inhibiting Ras signaling pathway.

  2021cites this paper
• Advances in Treatment Selection for Patients with Metastatic Colorectal Cancer

  2021cites this paper
• Co-administration of 5FU and propolis on AOM/DSS induced colorectal cancer in BALB-c mice.

  2021cites this paper
• Temporal Change in Treatment Patterns of Metastatic Colorectal Cancer and Its Association with Patient Survival: A Retrospective Cohort Study Based on an Intelligent Big-Data Platform

  2021cites this paper
• Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab

  2021cites this paper
• Minimizing the risk of small-for-size syndrome after liver surgery.

  2021cites this paper
• Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis

  2020cites this paper
• ERKRANKUNGEN DER VERDAUUNGSORGANE

  2020cites this paper
• Nanomaterial‐mediated platinum drug‐based combinatorial cancer therapy

  2020cites this paper
• Transarterial 90Yttrium Radioembolisation

  2020cites this paper
• Prognostic Value of the Pace of Tumor Progression as Assessed by Serial 18F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial

  2020cites this paper
• The conversion of RAS status in metastatic colorectal cancer patients after first‐line biological agent treatment

  2020cites this paper
• Real-world patterns of chemotherapy administration and attrition among patients with metastatic colorectal cancer

  2020cites this paper
• Prognostic Relevance of HJURP Expression in Patients with Surgically Resected Colorectal Cancer

  2020cites this paper
• Epidemiology and Socioeconomic Impact of CNS Metastases

  2020cites this paper
• Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia

  2020cites this paper
• Magnetic resonance spectroscopy and its application in colorectal cancer diagnosis and screening: A narrative review.

  2020cites this paper
• Dipeptidyl Peptidase 9 Increases Chemoresistance and is an Indicator of Poor Prognosis in Colorectal Cancer

  2020cites this paper
• Identification of the Effects of Aspirin and Sulindac Sulfide on the Inhibition of HMGA2-Mediated Oncogenic Capacities in Colorectal Cancer

  2020cites this paper
• Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study

  2020cites this paper
• Bone Metastases in Newly Diagnosed Colorectal Cancer by Tumor Location: a Population-based Study

  2020cites this paper
• Supramolecular combination chemotherapy: a pH-responsive co-encapsulation drug delivery system

  2020cites this paper
• Лекарственная радиомодификация местно-распространенного рака прямой кишки

  2020cites this paper